



(51) International Patent Classification:

A61K 51/08 (2006.01) A61K 103/00 (2006.01)

A61K 101/02 (2006.01)

(21) International Application Number:

PCT/EP2021/067653

(22) International Filing Date:

28 June 2021 (28.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2050786-9 29 June 2020 (29.06.2020) SE

(71) Applicants: **ANTAROS MEDICAL AB** [SE/SE]; Bioventure Hub, Pepparedsleden 1, 431 83 Mölndal (SE). **ANTAROS TRACER AB** [SE/SE]; c/o Antaros Medical AB, Bioventure Hub, Pepparedsleden 1, 431 53 Mölndal (SE).

(72) Inventors: **ERIKSSON, Olof**; Källbovägen 2 L, 756 46 Uppsala (SE). **KORSOREN, Olof**; Tallmovägen 2 A, 756 45 Uppsala (SE). **WESTERLUND, Christer**; Ålegårdsgatan 18, 431 50 Mölndal (SE). **WAGNER, Michael**; c/o Antaros Medical AB, Bioventure Hub, Pepparedsleden 1, 431 53 Mölndal (SE).

(74) Agent: **VALEA AB**; Box 1098, 405 23 Göteborg (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: COMPOUNDS FOR USE IN DIAGNOSIS AND/OR MONITORING OF FIBROSIS






Figure 8



(57) Abstract: There is provided a composition comprising: (i) a compound of Formula I: (I), or a pharmaceutically acceptable salt thereof, and (ii) a nuclide M, or a pharmaceutically acceptable salt of the compound of Formula I and/or the nuclide M, wherein C is a chelator selected from the group consisting of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (TETA), diethylenetriaminepentaacetic acid (DTPA), desferrioxamine B (DFO), 1,4,7-Triazacyclononane-1-glutaric acid-4,7-acetic acid (NOTAGA), 2-[4,7,10-Tris(carboxymethyl)-1,4,7,10-tetraza-1-cyclododecyl]glutaric acid (DOTAGA) and a derivative of any one of the foregoing chelators, L (Formula L) is a linker: (L), wherein m is an integer within the range of from 1 to 20, and X is NH or C(O) and forms an amide bond, i.e. C(O)NH, with a C(O) or NH moiety of the chelator, p is 0 or 1, Q is a peptide of SEQ ID NO: 1, a peptide analogue of SEQ ID NO: 1 having at least 88.8% identity to SEQ ID NO: 1, and/or a peptide of SEQ ID NO: 1, a peptide analogue of SEQ ID NO: 1 having at least 88.8% identity to SEQ ID NO: 1 and in which the C-terminal COOH can be replaced by CONH₂, and M is selected from the group consisting of ⁶⁸Ga, ¹⁸F, ⁶⁴Cu, ⁴⁴Sc, ⁸⁹Zr, ¹¹¹In, ⁶⁷Ga, ^{99m}Tc, Mn, Gd, ¹⁷⁷Lu, and ^{86/90}Y. The composition may be used in in diagnosing and/or monitoring of fibrosis.